Zosano Pharma Announces Pricing of Initial Public Offering
Tuesday, 27 January 2015

Fremont, California, January 27, 2015 — Zosano Pharma Corporation (NASDAQ: ZSAN) announced today the pricing of its initial public offering of 4,500,000 shares of common stock at a price to the public of $11.00 per share. The shares are scheduled to begin trading on the NASDAQ Capital Market under the ticker symbol "ZSAN" on January 27, 2015. All of the common stock is being offered by Zosano Pharma. In addition, Zosano Pharma has granted the underwriters a 30-day option to purchase up to 675,000 additional shares of common stock from Zosano Pharma. The offering is expected to close on January 30, 2015, subject to customary closing conditions.

Ladenburg Thalmann and Roth Capital Partners are acting as joint book-running managers.

Read more...
 
PRESS RELEASE
Tuesday, 02 December 2014

Zosano Pharma and Eli Lilly and Company Enter into Exclusive Licensing Agreement for Zosano’s ZP-PTH Product Candidate

Fremont, California and Indianapolis, December 2, 2014 — Zosano Pharma Corporation (Zosano) and Eli Lilly and Company (NYSE: LLY) today announced that they have entered into an exclusive agreement to develop ZP-PTH, Zosano’s proprietary formulation of parathyroid hormone 1-34 (PTH) using Zosano’s microneedle patch system for the treatment of osteoporosis patients, globally. Zosano has completed a Phase 2 study of ZP-PTH for the treatment of severe osteoporosis, and plans to conduct Phase 3 development.

Read more...
 
Zosano Pharma Appoints Troy Wilson, Ph.D., J.D., to Board of Directors
Wednesday, 25 June 2014

Fremont, California, June 25, 2014 – Zosano Pharma Corporation, a privately held pharmaceutical company developing products based on its novel transdermal delivery technology, today announced the election of Troy Wilson, Ph.D., J.D., to its Board of Directors. Dr. Wilson has more than 15 years of experience in the biotechnology industry and a proven track record of building highly successful biopharmaceutical companies. The appointment increases Zosano Pharma’s board membership to six.

Read more...
 
Zosano Pharma Files Registration Statement for Proposed Initial Public Offering
Tuesday, 24 June 2014

Fremont, California, June 24, 2014 – Zosano Pharma Corporation (Zosano) announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) for a proposed initial public offering of shares of its common stock. All of the shares to be sold in the offering will be offered by Zosano. The number of shares to be offered and the price range for the offering have not yet been determined.

Read more...
 
Zosano Pharma, Inc. to Present at the 74th American Diabetes Association (ADA) Scientific Session
Saturday, 14 June 2014
CSO Dr. Peter Daddona to Share Data on Use of ZP-Glucagon Product Candidate in Healthy Volunteers

Fremont, CA – June 14, 2014 – Zosano Pharma, Inc., a privately held biopharmaceutical company developing products based on its novel transdermal delivery technology, announced that Peter Daddona, Ph.D., Chief Scientific Officer and Executive Vice President, Research & Development, will present data today on its ZP-Glucagon product candidate at the 74th American Diabetes Associations (ADA) Scientific Session, in San Francisco, California.

Read more...
 
<< Start < Prev 1 2 Next > End >>

Results 1 - 9 of 16
Contact   |   Sitemap   |   Legal
  |   Design: Formative